Predictors of Symptom Scores in Myeloproliferative Neoplasms: A Real‐World Retrospective Cohort Study
Integrating depression screening and management and optimizing hematologic parameters alongside disease-directed therapy is crucial to improving patient outcomes.
Authors
- Cecilia Y. Arana Yi (ORCID: https://orcid.org/0000-0002-7441-5140)
- Irbaz Bin Riaz (ORCID: https://orcid.org/0000-0003-4249-0311)
- Heidi Kosiorek (ORCID: https://orcid.org/0000-0002-4651-9516)
- John Camoriano (ORCID: https://orcid.org/0000-0002-2957-5356)
- Jeanne Palmer (ORCID: https://orcid.org/0000-0002-2185-1504)
- Joshua L. Blocher
- Syed Arsalan Ahmed Naqvi (ORCID: https://orcid.org/0000-0002-3131-2088)
- Jennifer Andres (ORCID: https://orcid.org/0000-0002-5537-980X)
- Muhammad Ali Khan (ORCID: https://orcid.org/0009-0002-0079-9935)
Institutions
- Mayo Clinic in Arizona (US)
- Mayo Clinic Hospital (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-11-29
- DOI
- https://doi.org/10.1002/cam4.71333
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00